| answer text |
<p>We have assumed the Hon. Member is referring to edaravone (Radicava). Edaravone
is not currently licensed or under assessment within the European Union for any indication
and the Department therefore has no such plans. If the manufacturer seeks a marketing
authorisation for edaravone in the United Kingdom or EU, it will be assessed for safety,
efficacy and quality through the established licensing process and then considered
through the topic selection process for possible assessment of clinical and cost effectiveness
by the National Institute for Health and Care Excellence (NICE).</p><p> </p><p>Where
a drug or treatment has not been appraised by NICE, funding decisions should be made
by the relevant National Health Service commissioner, based on an assessment of the
available evidence and on the basis of an individual patient’s clinical circumstances.</p>
|
 |
